Pharmacokinetic Assessment of Single-Dose Odanacatib (MK-0822) in Subjects With Severe Renal Insufficiency (MK-0822-067)
Status:
Completed
Trial end date:
2012-08-22
Target enrollment:
Participant gender:
Summary
This study will investigate and compare pharmacokinetics of a single 50 mg dose of odanacatib
administered to participants with impaired renal/kidney function to those of a healthy
matched control group. The primary hypothesis is that plasma AUC0-∞ of odanacatib in
participants with impaired renal function is similar to that in matched healthy participants
following a single 50 mg oral dose.